IO Biotech was a clinical-stage biopharmaceutical company developing immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win platform. Company news centered on Cylembio, also described as IO102-IO103, clinical data in advanced melanoma and other solid tumors, presentations of preclinical candidates including IO112 and IO170, and updates involving pembrolizumab combination studies.
News about IOBT also covered corporate presentations, financial results, strategic alternatives, cost-containment actions and workforce reductions before the company's Chapter 7 bankruptcy filing and cessation of operations.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.